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Background: 8-chloro-adenosine (8-Cl-Ado) is a unique ribonucleoside analog which is currently in a phase I clinical
trial for hematological malignancies. Previously, we demonstrated in breast cancer cells that a 3-day treatment with
10 μM 8-Cl-Ado causes a 90% loss of clonogenic survival. In contrast, there was only a modest induction of apoptosis
under these conditions, suggesting an alternative mechanism for the tumoricidal activity of 8-Cl-Ado.
Methods: Cellular metabolism, AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR)
pathway signaling, as well as autophagy induction was evaluated in breast cancer cell lines treated with 8-Cl-Ado. The
effects of knocking down essential autophagy factors with small interfering RNA on 8-Cl-Ado-inhibited cell survival was
assessed in breast cancer cells by examining apoptosis induction and clonogenic survival. In vivo efficacy of
8-Cl-Ado was measured in two breast cancer orthotopic model systems.
Results: We demonstrate that in breast cancer cell lines, the metabolism of 8-Cl-Ado results in depletion of endogenous
ATP that subsequently induces the phosphorylation and activation of the energy sensor, AMPK. This was associated with
an attenuation of mTOR signaling and an induction of the phosphorylation of the autophagy factor, Unc51-like kinase 1
on Ser555. 8-Cl-Ado-mediated induction of autophagy was evident by increased aggregates of microtubule-associated
protein 1 light chain 3B (LC3B) which was associated with its conversion to its lipidated form, LC3B-II, p62 degradative
flux, and increased formation of acidic vesicular organelles. Additionally, transfection of MCF-7 cells with siRNA to ATG7
or beclin 1 provided partial protection of the cells to 8-Cl-Ado cytotoxicity as measured by clonogenicity. In vivo,
8-Cl-Ado inhibited growth of both MCF-7 and BT-474 xenograft tumors. Moreover, in 9 of 22 BT-474 tumors treated with
100 mg/kg/day 3 times a week, there was an absence of macroscopically detectable tumor after 3 weeks of treatment.
Conclusions: Our data demonstrates that 8-Cl-Ado treatment activates the AMPK pathway leading to autophagy
induction of in breast cancer cells, eliciting, in part, its tumoricidal effects. Additionally, 8-Cl-Ado effectively inhibited
in vivo tumor growth in mice. Based on this biological activity, we are planning to test 8-Cl-Ado in the clinic for patients
with breast cancer.
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Breast cancer is the most prevalent cancer in women in
industrialized countries. Each year more than a half million
new cases of breast cancer are diagnosed in the US and
Europe. Although in recent years, advances in therapies
have contributed to decreased mortality; worldwide nearly* Correspondence: cmstellre@mdanderson.org
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addition, toxicity associated with current treatments and
the risk of developing secondary cancers [1] highlight the
urgent need for new therapies against the disease.
8-chloro-adenosine (8-Cl-Ado) is a unique ribonucleoside
analog that is currently in a phase I clinical trial at the UT
MD Anderson Cancer Center for the treatment of chronic
lymphocytic leukemia (CLL). Previously, we demonstrated
this analog is tumoricidal to breast cancer cells [2]. Inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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inhibits the growth and survival of numerous other
hematological and solid tumor model systems [3-19] but
not normal lymphocytes [12] or non-transformed mam-
mary epithelial cells (unpublished data).
Much of our prior work on the cytotoxic effects of
8-Cl-Ado focused on the accumulation of 8-Cl-ATP
[2,8-10,12,20] and its incorporation into mRNA [10]
preceding an inhibition of transcription [2,8-10,12,19] and
poly(A) polymerase [21,22]. The net effects of these events
lead to an induction of apoptosis [2,8-10,12]. In breast
cancer cells, 8-Cl-Ado-induced cytotoxicity is only par-
tially attributed to apoptosis. In addition to the impact on
transcription, 8-Cl-Ado-induces a reduction of the intra-
cellular ATP pool [2,8-10,12] and ATP depletion has been
associated with apoptosis-independent cell death [23,24].
Within the cell, ATP levels are tightly regulated by
AMP-activated protein kinase (AMPK), which functions
as a cellular energy sensor [25]. AMP and ATP directly
bind and regulate AMPK such that when ATP levels
decrease, AMP is allowed to bind and allosterically ac-
tivate AMPK. Additionally, upstream kinases can then
phosphorylate and further activate AMP bound AMPK.
Once activated, AMPK promotes events that lead to meta-
bolic switches to restore cellular bioenergy. Significant
energy regulating effects of AMPK pertaining to cancer
therapeutics is its ability to attenuate growth and protein
synthesis by regulating mammalian target of rapamycin
(mTOR) pathway and induce autophagy.
AMPK inhibition of mTOR signaling occurs through
two pathways. First, AMPK directly phosphorylates and
activate tuberous sclerosis protein 2 which is involved in
mTOR inhibitory signaling. Second, AMPK has been
shown to phosphorylate and inactivate raptor, a member
of mTORC1. Both mTORC1 and AMPK regulate autoph-
agy through the phosphorylation of Unc51-like kinase 1
(ULK1). [For a review see ref. [26]]. ULK1 is a mammalian
homolog of a yeast autophagy initiating factor, Atg1.
Although there has been some discrepancy regarding
the specific AMPK phosphorylation sites on ULK1, it is
clear that AMPK activates ULK1 while the phosphorylation
by mTORC1 inhibits ULK1 activity. AMPK also regulates
autophagy through modulation of components of Vsp34
complexes [27].
The events above delineate the mode by which di-
minished ATP levels can alter cellular processes. Since
8-Cl-Ado treatment diminishes the ATP pool [2,8-10,12],
we hypothesize that 8-Cl-Ado treatment will educe AMPK
activation and mTORC1 attenuation which will initiate
autophagy. Our current investigation further evaluated the
cellular metabolism of 8-Cl-Ado and its metabolic effects
on bioenergy. Moreover, we examined the mechanism
of action of the bioenergy depletion that leads to a non-
apoptotic cell death in breast cancer cells.Results
8-Cl-Ado accumulation/elimination and effects on energy
production
Previously, our group demonstrated that 8-Cl-Ado
(Figure 1A) is tumoricidal to primary CLL lymphocytes
[12], breast cancer [2], myeloma [17], and mantle cell
lymphoma (MCL) [8] cell lines and this cytotoxicity was
dependent on the analog’s metabolism to its monopho-
sphate form by adenosine kinase [9] followed by triphos-
phate accumulation. In the breast cancer cell lines, we
showed that a 3-day treatment with 10 μM 8-Cl-Ado
inhibited over 90% clonogenic survival [2] (Figure 1B).
Paradoxically, we demonstrated that such treatments were
associated with only a ~30% induction of apoptosis in both
cell lines as measured by annexin V and PI staining [19]
(Figure 1C and Additional file 1: Figure S1).
We established that 8-Cl-Ado treatment results in a
rapid depletion of ATP within 12-hours which was as-
sociated with 8-Cl-ATP accumulation (Additional file 1:
Figure S2 and [2]). To examine the impact of 8-Cl-Ado
treatment on energy producing metabolic pathways, we
analyzed both glycolysis and mitochondrial respiration.
Extracellular acidification rate (ECAR), as a measure of
glycolysis, and oxygen consumption rate (OCR), for mito-
chondrial respiratory function, were assessed in both MCF-
7 and BT-474 cells treated with and without 8-Cl-Ado for
18 hr using a Seahorse XF96 analyzer. Our results indicated
that, both basal mitochondrial respiration (Figure 2A,
B, and C) and glycolysis (Figure 2D) were perturbed by
8-Cl-Ado treatment. The finding of decreased O2 con-
sumption is in keeping with previous data which indicated
8-Cl-Ado may be an inhibitor of mitochondrial complex
V, ATP synthase [28]. The alteration in glycolysis may
possibly be associated with decreased glucose uptake,
which was seen in myeloma cells treated with an 8-Cl-Ado
congener compound, 8-amino-adenosine [29]. Interestingly,
further assessment of cellular respiratory chain with XF
Cell Mito Stress Test assay possibly revealed addition
alterations in cellular respiration induced by 8-Cl-Ado
treatment, as OCR was still attenuated even after the
addition of an uncoupler, FCCP, to alleviate the depend-
ency of complex I-IV on complex V’s transport of electrons
across the mitochondrial membrane (Figure 2B and C).
Because tumor cells are known to be sensitive to ATP
depletion, we decided to assess the effects of 8-Cl-Ado on
ATP levels throughout the 3-day treatment. Our results
showed that in BT-474 cells the ATP levels continued to
diminish over a 3-day treatment with 10 μM 8-Cl-Ado
(Figure 2E) while in MCF-7 cells the levels remained
below control levels but did show evidence of some recovery
by 24-hours. Additionally, we examined the accumulation
of the analog’s cytotoxic metabolite, 8-Cl-ATP, over
72-hours. The accumulation of the analog triphosphate
inversely paralleled the ATP depletion as it peaked at
Figure 1 Effect of 8-Cl-Ado on the survival of breast cancer cells. (A) Structure of 8-Cl-Ado. (B) The effects of 8-Cl-Ado on the clonogenic
growth of MCF-7 cells. Cells were treated with 10 μM 8-Cl-Ado for 3-days, washed with PBS, and cultured in fresh medium for 14-days. Colonies
of >50 cells were counted under a dissecting microscope. (C) Flow cytometery analysis of annexin V and PI staining in MCF-7, hatched bars, and
BT-474 cells, black bars, treated with 10 μM 8-Cl-Ado for the indicated times.
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(Figure 2F). Since the ratio of 8-Cl-ATP to ATP has
been shown to be a determinant of the cytotoxic effect
of 8-Cl-Ado [2,8], the kinetics of this relationship was
also examined (Figure 2G). We demonstrated that the
ratio of the analog triphosphate to normal ATP was high-
est in MCF-7 cells which rapidly peaked at 12-hours while
in BT-474 cells the ratio continually increased until it
reached a plateau by 24-hours. The elimination kinetics
of 8-Cl-ATP was also measured by treating the cells
with 10 μM 8-Cl-Ado for 3-days, washing drug off and
continued culturing the cells in drug-free medium for
another 3-days (Figure 2H). In both lines there appeared
to be an initial, more rapid elimination of 8-Cl-ATP after
drug removal. If a biphasic elimination kinetics is consid-
ered, the 8-Cl-ATP half-lives in MCF-7 cells were 3.8- and
25.5-hours while in BT-474 it was 6.4-hours and >7-days.
An assessment of the kinetics as a monophasic elimin-
ation yields the 8-Cl-ATP half-lives as 5.8 and 11.4-hours
for MCF-7 and BT-474, respectively.
8-Cl-Ado induces AMPK activity in breast cancer cells
The 8-Cl-Ado-induced ATP depletion is expected to
increase the AMP to ATP ratio which would lead to
activation of AMPK. To determine if 8-Cl-Ado is able to
induce AMPK activity, we treated MCF-7 and BT-474
cells with 10 μM 8-Cl-Ado for various times and assessed
changes in p-AMPK (Thr172) levels by immunoblot
analysis. The results demonstrated that while total AMPK
protein levels were unchanged by 8-Cl-Ado treatment,
phosphorylation of AMPK (Thr172) was induced in a
time-dependent manner, being readily detected within
7- to 12-hours (Figure 3A). To further assess AMPK ac-
tivity, we examined the cellular phosphorylation of oneof its critical downstream substrates, ACC on Ser79 and
showed that AMPK activity is induced within 4-hours of
8-Cl-Ado treatment (Figure 3B). These events occurred in
both MCF-7 and BT-474 cells which indicate they do not
require p53 as MCF-7 cells have a wild type p53 genotype
while BT-474 cells harbor a mutant p53 [30].
Inhibition of mTOR by 8-Cl-Ado
A significant energy regulating effect of AMPK per-
taining to cancer therapeutics is the ability of AMPK to
inhibit the mTOR pathway. To determine if the 8-Cl-
Ado-dependent AMPK induction altered the activity of
the mTOR pathway, we assessed the effects of 8-Cl-Ado
on Ser792 residue of raptor; an AMPK phosphorylation
site on this mTORC1 protein. We determined that 10 μM
8-Cl-Ado-treatment readily induced the phosphorylation
of raptor Ser792 (Figure 4A) in MCF-7 cells. This was
associated with diminished mTOR autophosphorylation
on Ser2481 (data not shown). To further assess mTORC1
activity, we examined the phosphorylation status of the
mTORC1 target, 4E-BP1, and found 8-Cl-Ado treat-
ment diminished the level of p-4E-BP1 (Ser65), a rapa-
mycin sensitive phosphorylation site [31] and reduced
the levels of the slower migrating hyperphosphorylated
4E-BP1 bands (Figure 4B). Overall, these results demon-
strate 8-Cl-Ado treatment attenuated mTOR activity in
breast cancer cells.
8-Cl-Ado-induced activation of ULK1
AMPK and mTOR are both able to regulate autophagy
through direct phosphorylation of Unc51-like kinase 1
(ULK1), which is the human counterpart of the yeast
autophagy initiating factor, Atg1. Although there has been
some discrepancy as to the ULK1 phosphorylation sites,
Figure 2 Accumulation and elimination of 8-Cl-ATP and effects on ATP production. (A) 10 μM 8-Cl-Ado treatment, hatched bars, perturbs
basal OCR as compared to untreated, solid bars, in MCF-7, gray bars, and BT-474 cells, black bars. Effects of altering ETC complexes with the agents,
oligomycin, FCCP, antimycin, and rotenone on OCR in (B) MCF-7 and (C) BT-474 cells treated with, black circles, and without, gray circles, 10 μM
8-Cl-Ado. (D) 10 μM 8-Cl-Ado treatment, hatched bars, reduces basal glycolysis as demonstrated by decreased ECAR in MCF-7, gray bars, and BT-474
cells, black bars. (E) Time dependent depletion of the endogenous ATP pool, (F) the accumulation of 8-Cl-ATP, and (G) changes in the 8-Cl-ATP/ATP
ratio in MCF-7, ○, and BT-474 cells, ●. Cells were treated with 10 μM 8-Cl-Ado for the indicated times and acid extracts were analyzed by HPLC
to measure nucleotide levels. (H) The elimination of 8-Cl-ATP in MCF-7, ○, and BT-474 cells, ●. Cells were treated with 10 μM 8-Cl-Ado for 3 days,
washed with PBS, and cultured in fresh medium. At the indicated times, acid extracts were analyzed as above.
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AMPK directly phosphorylates ULK on Ser555 [32-35].
We examined the effects of 8-Cl-Ado on the AMPKphosphorylation of this site and determined that 10 μM
8-Cl-Ado-treatment induces ULK1 phosphorylation on
Ser555 in MCF-7 and BT-474 cells (Figure 5A).
Figure 3 Dose and time dependent induction of AMPK activity
after treatment with 8-Cl-Ado. Immunoblot analysis of phospho- and
total AMPKα levels (A) in MCF-7 and BT-474 cells treated with 10 μM
of 8-Cl-Ado for the indicated times. (B) Analysis of the phosphorylation
levels of the AMPK target, ACC, in MCF-7 and BT-474 cells treated as
described above. The normalized ratio of p-ACC to GAPDH relative to
the untreated control is indicated beneath each lane. GAPDH was used
as a loading control for all immunoblots.
Figure 4 8-Cl-Ado inhibits the activity of the mTOR pathway.
Immunoblot analysis of 8-Cl-Ado-induced (A) phosphoylation of
raptor on the AMPK phosphorylation site, Ser792, as compared with
total raptor and (B) specific inhibition of an mTOR phosphorylation
site on 4E-BP1 Ser65 along with compression of slower migrating
hyperphosphorylated 4E-BP1 bands in MCF-7 and BT-474 cells treated
with 10 μM of 8-Cl-Ado for the indicated times. The normalized ratios
of p-raptor Ser792 to GAPDH and of p-4E-BP1 Ser65 to total relative to
the untreated control is indicated beneath their respective lane.
GAPDH was used as loading controls for all blots.
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Because both AMPK activation and mTOR inhibition can
induce autophagy and 8-Cl-Ado treatment induced ULK1
Ser555 phosphorylation, we investigated whether 8-Cl-Ado
would generate an autophagic response. To assess autop-
hagosome formation, we used immunoblot analysis to
evaluate lipidation of cleaved LC3B-I to the faster migrat-
ing autophagosome marker, LC3B-II. 8-Cl-Ado induced
LC3B-I and LC3B-II protein levels in both MCF-7 and
BT-474 cells (Figure 5B). Additionally, fluorescent micros-
copy of MCF-7 and BT-474 cells transfected with a LC3B-
GFP expression construct, demonstrated that 8-Cl-Ado
induced LC3B aggregation (Figure 5C), which further
provides evidence of autophagosomes formation. Dynamic
changes or flux in p62/SQSTM1 levels are also an indica-
tion of autophagy. This is due to the accumulation of p62
bound protein aggregates being sequestered during phago-
some formation, followed by depletion because of autoly-
sosomal degradation. 8-Cl-Ado treatment of MCF-7 and
BT-474 cells induced an autophagic flux in both LC3B-II
and p62 levels (Figure 5B and D).
Demonstration of autolysosome formation was performed
by confocal microscopy of live MCF-7 cells stained with
monodansylcadaverine (MDC) and syto61 which stains
acidic vesicular organelles (AVO) and DNA, respectively
(Figure 5E). The mTOR inhibitor, rapamycin, was usedas a positive control. MDC staining of large AVO increased
in 10 μM 8-Cl-Ado treated MCF-7 cells similar to treat-
ment with 50 nM rapamycin. To quantitate the levels of
AVO induction, 8-Cl-Ado treated MCF-7 and BT-474
cells were stained with acridine orange and assessed by
flow cytometry (Figure 5F and G). Rapamycin and Bafi-
lomycin A1 (Baf ) treatment were used as positive and
negative controls, respectively. As with the MDC staining,
there is an induction of acridine orange staining of AVO
in 8-Cl-Ado treated MCF-7 and BT-474 cells to levels
similar to treatment with rapamycin. After 3-days of treat-
ment, there were an 18 and 14% increase in AVO staining
with 10 μM 8-Cl-Ado in MCF-7 and BT-474 cells, re-
spectively which was comparable to the 14 and 10%
increase seen with 50 nM rapamycin treatment over
the same time. Similar results were seen in 8-Cl-Ado
treated T47D, SK-BR-3, and ZR-75-1 cells (Additional
file 1: Figure S3). Collectively, these results establish
that 8-Cl-Ado induces autophagy in breast cancer cells.
Figure 5 8-Cl-Ado-induces autophagy. Immunoblot analysis of (A) phospho-ULK (Ser555) levels and (B) LC3B-I lipidation to form LC3B-II in
MCF-7 and BT-474 cells treated with 10 μM of 8-Cl-Ado for the indicated times. (C) Fluorescent microscopy of MCF-7 and BT-474 cells transiently
transfected with GFP-LC3B and treated with 10 μM of 8-Cl-Ado for 12-hours to assess aggregation of LC3B. (D) Immunoblot analysis of p62 levels
in MCF-7 and BT-474 cells treated with 10 μM of 8-Cl-Ado for the indicated times. The normalized ratio of p62 to GAPDH relative to the untreated
control is indicated beneath each lane. (E) Fluorescent microscopic imaging of autolysosomes. MCF-7 cells were untreated or treated for 2-days
with 8-Cl-Ado or rapamycin. Cells were stained with MDC, blue, to visualize AVO and Syto 61 (DNA), red, for nuclei counterstaining. (F) Representative
flow cytometery histograms of AVO stained with acridine orange in MCF-7 cells untreated or treated for 3 days with 50 nM rapamycin or 10 μM 8-Cl-Ado.
Baf was added before 30 min prior to staining to neutralize AVO staining. (G) Quantification triplicate experiments of MCF-7 and BT-474 cells treated
and analyzed as in E.
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induced cytotoxicity
Previously, we had noted that with a 3-day treatment of
10 μM 8-Cl-Ado there was a ~90% loss of clonogenic
survival while the amount of apoptosis induction only
reached ~30% [2] (Figure 1B and C), suggesting there
is another mechanism of cell killing occurring in the
8-Cl-Ado treated breast cancer cells. One possibility is
through autophagic cell death. To test this hypothesis,
we transfected MCF-7 cells with small interfering RNA
(siRNA) directed against ATG7, or BECN1, which arerequired autophagy factors, and compared 8-Cl-Ado
treatment of these cells to MCF-7 cells transfected with
siCONT. The targeting siRNAs effectively depleted their
respective targets during the 3 days of 8-Cl-Ado treat-
ment and blocked autophagy induction (Figure 6A and
C). Interestingly, although siBECN1 and siATG7 did
not alter the extent of 8-Cl-Ado-induced apoptosis
(Figure 6A and B), they did increase clonogenic survival
(Figure 6D and E). These results indicate that 8-Cl-
Ado cytotoxicity is mediated in part by autophagic cell
death.
Figure 6 8-Cl-Ado-induces autophagic cell killing. (A) Western
blot analysis of beclin1 and ATG7 levels in MCF-7 cells transfected
with either a pool of control siRNA (siCONT), siRNA targeting the
expression of the beclin1 gene (siBECN1), or targeting the expression
of the ATG7 gene (siATG7). Immunoblot analysis of LC3B lipidation
and PARP cleavage were assessed as markers of autophagosome
formation and apoptosis, respectively. GAPDH was used as loading
control. Flow cytometric analysis of cells transfected with siCONT,
solid bars, siBECN1, hatched bars, or siATG7, checkered bars, treated
with 10 μM 8-Cl-Ado and stained with (B) annexin V and PI, as well
as (C) acridine orange. Effect of autophagy on 8-Cl-Ado-inhibiton of
clonogenic survival. Cells transfected with (D) siCONT, ○, or siBECN1,
●, and with (E) siCONT, ○, or siATG7, ●, were treated with the
indicated doses of 8-Cl-Ado for 3 days, washed with PBS, and cultured
in fresh medium for 10 days. Colonies of >50 cells were counted under
a dissecting microscope.
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cancer models
Our studies demonstrated 8-Cl-Ado is tumoricidal to
breast cancer cells in cultures. To determine the efficacy
of 8-Cl-Ado in vivo we established both MCF-7 and
BT474 orthotopic tumors in nu/nu mice. Upon tumor
formation, mice were treated for 3 weeks with varying
doses up to 100 mg/kg/d 8-Cl-Ado 3d per week. Previous
in cellular pharmacology analyses performed on peripheral
blood mononuclear cells from CD2F1 mice after i.v. ad-
ministration of 50 and 100 mg/kg 8-Cl-Ado, showed the1 hr accumulation of 8-Cl-ATP was ~350 and ~1150 μM,
respectively, [20] which was higher than the accumulation
seen in the breast cancer cell lines treated with 10 μM
8-Cl-Ado [2], indicating tumoricidal doses are readily
achievable. Additionally, an extensive toxicology assess-
ment of numerous hematology, clinical chemistry, and
microscopic pathology parameters of 8-Cl-Ado treatment
in CD1 mice showed no toxicity at these doses [36].
In the current study our results showed growth of
the MCF-7 tumors were suppressed by the 100 mg/kg
8-Cl-Ado treatment (Figure 7A) which showed statistically
significant differences by day 10 of treatment. Addition-
ally, there was a dose dependent inhibition in a compari-
son of 0, 25, 50, and 100 mg/kg doses (data not shown).
The growth of BT-474 tumors was dramatically altered
as growth was significantly inhibited by the third day of
treatment (Figure 7B). Furthermore, many of the tumors
showed regression with the 100 mg/kg 8-Cl-Ado treatment.
A 50 mg/kg dose did not affect the growth of the BT-474
xenograft tumors (data not shown). Similarly, an assess-
ment of the final, excised tumor volume again showed
mice treated with 100 mg/kg 8-Cl-Ado had statistically
smaller MCF-7 and BT-474 tumor volumes after comple-
tion of the treatment (Figure 7C and D). Moreover, 9 of
20 BT-474 tumors completely regressed macroscopically.
These results establish the potential for 8-Cl-Ado as a
therapeutic agent to treat breast cancer and indicate
BT-474 orthotopic tumors have a higher sensitivity to
8-Cl-Ado.
Discussion
Previously, our investigations on the cytotoxic effects of
8-Cl-Ado focused on the accumulation of 8-Cl-ATP and
its inhibitory effects on transcription [2,8-10,12]. In breast
cancer cells, 8-Cl-Ado-induced cytotoxicity is only par-
tially attributed to apoptosis. Depletion of the intracellular
ATP pool has been associated with apoptosis-independent
cell death [23,24]. Since 8-Cl-Ado treatment diminishes
the ATP pool (Figure 2A) [2,8-10,12], the objective of the
current study was to further evaluate 8-Cl-Ado metabolic
effects on the cells and its involvement with non-apoptotic
cell death in the breast cancer cell lines. Data presented in
the present work indicates 8-Cl-Ado perturbs bioenergy
production in breast cancer cells by altering both glycolysis
and mitochondrial respiration. The resulting ATP depletion
induces AMPK activation, leading to an attenuation of
mTOR signaling and an induction of autophagic cell death.
Previous evidence suggested that the mode by which
8-Cl-Ado leads to ATP depletion is due to the analog’s
metabolite, 8-Cl-ADP, being a substrate for ATP synthase
for conversion to 8-Cl-ATP [28]. In that study, both
the di and tri phosphate of 8-ClAdo were found to affect
complex V, ATP synthase. Based on molecular modeling,
8-Cl-ATP was shown to fit well in the product site which
Figure 7 Efficacy of 8-Cl-Ado in breast cancer xenograft models. MCF-7 and BT474 xenografts in nude mice were established as described in
Materials and Methods. Mice were treated with control PBS (0 mg/kg) or 8-Cl-Ado (100 mg/kg) three times a week for 3 weeks. MCF-7 (A) and
BT-474 (B) tumor growth during 8-Cl-Ado treatment were assessed by measuring maximum tumor diameter each day of treatment. Final MCF-7
(C) and BT-474 (D) tumor volumes of tumors excised within 3 days of the final treatment. Statistical significance was determined using an unpaired
t-test was used to, *P < 0.05, **P < 0.01, ***P < 0.001.
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catalytic site, thus inhibiting catalysis of its natural
substrate ADP to synthesize ATP. Our evaluation of basal
mitochondrial respiration in breast cancer cells treated
with 8-Cl-Ado is in agreement with this study’s finding on
8-Cl-Ado treatment inhibiting complex V activity.
Additionally, our data from the Mito Stress Test suggests
8-Cl-Ado also alters a component(s) of complex I-V of the
electron transport chain complex (ETC) as well. This is in
contrast to the prior study [28] which concluded 8-Cl-Ado
treatment did not affect complex I-IV. Their premise was
based on similar O2 consumption rate in cells treated with
8-Cl-Ado versus adenosine. While our analysis did not
evaluate the effects of adenosine on these cells, our
conclusions are based on the use of an uncoupler, FCCP,
which allows complex I-V to work at full function even
when complex V is inhibited. Under these conditions,
the 8-Cl-Ado treated breast cancer cells still showed
depressed rates of O2 consumption. One possible mech-
anism by which 8-Cl-Ado may be affecting the ETC is
through disturbing the citric acid cycle. In MCL cells,
8-Cl-AMP was found to be metabolized to both 8-Cl-ATPand to succinyl-8-Cl-Ado [37]. The high metabolism to
a succinylated moiety in MCL cells depleted fumarate,
a component of the citric acid cycle. In MCL cells, the
accumulation of succinyl-8-Cl-Ado was greater than 8-Cl-
ATP. While high accumulation of succinyl-8-Cl-AMP was
not seen in MCF-7 or BT-474 cells as the levels of
succinyl-8-Cl-Ado reached less than 10% of the 8-Cl-ATP
levels (unpublished data), it does suggests 8-Cl-Ado may
have some degree of an effect on the citric acid cycle in
breast cancer cells. Additional studies are ongoing to
determine what component(s) of the ETC is affected by
8-Cl-Ado treatment.
Besides metabolism to succinyl-8-Cl-Ado, the analog
may be indirectly affecting ATP production through alter-
ing glycolysis. An 8-Cl-Ado congener compound, 8-amino-
adenosine has been shown to alter the localization and
expression of glucose transporters, and reduce glucose
consumption, in myeloma cells [29]. Thus, it probable
that 8-Cl-Ado may also be altering glycolysis in breast
cancer cells through similar mechanisms.
In the breast cancer cells, we found the 8-Cl-Ado-me-
diated depletion of the endogenous cellular ATP pool
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ylation and activity as measured by phosphorylation of
AMPK target proteins, ACC and raptor. In agreement
with our work, both Han et al. [38] and Lucchi et al.
[39] showed that 8-chloro-cyclic AMP (8-Cl-cAMP) also
activates AMPK. Our group and others have demonstrated
that 8-Cl-cAMP serves as prodrug for 8-Cl-Ado, as the
cyclic analog is converted extracellularly in plasma or in
medium to 8-Cl-Ado via the enzymatic actions of serum
phosphodiesterase and 5′-nucleotidase [6,7,17,40]. In
concert, studies using an adenosine kinase deficient cell
line demonstrated that 8-Cl-cAMP needs to be converted
to 8-Cl-Ado and metabolized to 8-Cl-AMP intracellularly
to induce its cytotoxic effects [9]. In both studies by Han
et al. [38] and Lucchi et al. [39], the authors went
on to further examine the growth inhibitory effects of
8-Cl-cAMP-induced AMPK activity on p38 mitogen-
activated protein kinase to induce apoptosis. Both groups
conclusively demonstrated that 8-Cl-cAMP mediated
AMPK and p38 activation promoted the growth inhibitory
and apoptotic effects of 8-Cl-cAMP, as combinations with
the p38 inhibitors attenuated these events.
It is also interesting to note that while the induction
of AMPK and autophagy occurred in both MCF-7 and
BT-474 cells, the induction was not as robust in the
BT-474 cells. For example, phosphorylation of ACC
reached 3.8 fold increase in MCF-7 and 1.5 fold in BT-
474; flux in p62 levels in MCF-7 increased to 1.70 fold
and then decreased down to 0.67 fold while in BT-474
increased to 1.13 fold and then decreased down to 0.77
fold change. MCF-7 and BT-474 cells are p53 wild type
and mutant [30], respectively; thus, the occurrence of
AMPK and autophagy induction in both cell lines indi-
cates these events do not require p53. However, since
there was less induction in BT-474 cells, this may suggest
there might be some dependency on p53 to achieve the
same level of induction as seen in MCF-7 cells. Though
this notion is intriguing, additional studies would be
needed to explore the possibility of p53 status playing
a role in the differential induction levels. A study of 8-
amino-adenosine in breast cancer cell lines MCF-7 and
MDA-MB-231 (p53 mutant) cell lines also showed this
analog was able to induce apoptosis and autophagy in
both cell lines, though the mechanism for the autophagy
induction was not examined [41]. Moreover, in agreement
with our work, this study showed that inhibition of au-
tophagy did not affect the level of apoptosis. Because
clonogenic survival was not examined in this study, it
is unclear if the inhibition of autophagy affected this
survival.
Agents with AMPK agonist activity have generated con-
siderable interest for use in cancer therapeutics [reviewed
in [25]]. The diabetes drug, metformin, is believed to be
an oxidative phosphorylation inhibitor that inducesAMPK through its ability to decrease ATP levels. Metfor-
min has been shown to suppress spontaneous tumor for-
mation in various animal models as well as suppress
in vitro and in vivo tumor growth. Moreover, several stud-
ies have shown metformin reduces cancer risks in diabetic
patients as well as improved therapeutic response in those
with breast cancer. Interestingly, in vivo studies in mouse
model systems indicate both p53 deficient [42] and HER2
over expressing tumor cells [43] have an increased sen-
sitivity to metformin treatment. Similarly, we demon-
strated 8-Cl-Ado had the highest efficacy in the BT-474
xenograft tumors which are both p53 deficient and
HER2 over expressing. While 8-Cl-Ado inhibited the
growth of both MCF-7 and BT-474 xenograft tumors, 45%
of the BT-474 tumors were no longer detectable macro-
scopically after a 3 week treatment with 100 mg/kg dose.
A study by Cheong et al. demonstrated that metformin in
combination with the glycolysis inhibitor, 2-deoxyglucose,
activated AMPK, inhibited mTORC1 and induced autoph-
agy [23]. Furthermore, the authors stated that in 13 of
15 cancer cell lines tested, this combination was more
cytotoxic than either agent alone. Moreover, the increased
sensitivity of this couplet correlated with ATP depletion
and was associated with the down regulation of the expres-
sion of key components of the ETC complex I. In contrast,
combination of AICAR and 2-deoxyglucose was also able
to activate AMPK and inhibit mTORC1 but was not cyto-
toxic and did not deplete ATP. This was attributed to in-
creased expression of numerous genes in ETC I, II, III, IV
and FoF1-ATP synthase complexes, which would promote
ATP production. Although Cheong et al. did not evaluate
autophagy in the AICAR treated cells, it is important
to point out there is controversy as to whether AICAR
promotes or inhibits autophagy [44-46]. Their results
do indicate a superior therapeutic effect is achieved with a
dual inhibition of energy pathways for targeting tumor
bioenergetics. Based on our findings that 8-Cl-Ado is able
to perturb glycolysis as well as deplete ATP it is interest-
ing to speculate this ribonucleoside analog, as a single
agent, may achieve the dual effects seen with metformin
and 2-deoxy-glucose combination.
Conclusion
In summary, we show that 8-Cl-Ado is cytotoxic to breast
cancer cells and this cytotoxicity is mediated by both
apoptosis and autophagy. The 8-Cl-Ado-induced depletion
of ATP elicits the autophagic response through activation
of AMPK and inhibition of mTORC1; with the endpoint of
these events being the activation of an autophagy initiation
factor, ULK1, leading to the induction of autophagy.
This unique nucleoside analog is in a phase I clinical
trial for hematological malignancies. Preliminary analysis
of the cells from patients in the trial indicates ATP deple-
tion, AMPK activation, and induction of autophagy occurs
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(unpublished data). Taken together our results indicate
that targeting the bioenergy production of breast cancer
cells would be an effective strategy for treating this disease,
which can be readily achieved with 8-Cl-Ado.
Methods
Materials
8-Cl-Ado was obtained from Dr. V. Rao at the Drug
Development Branch of the National Cancer Institute
and was dissolved in water. Rapamycin (LC Laboratories,
Woburn, MA) and bafilomycin A1 (Baf) (Sigma-Aldrich,
St. Louis, MO) were dissolved in DMSO.
Cell culture, clonogenic assays, and transfection
MCF-7 and BT-474 cell lines were obtained from ATCC
(Manassas, VA) and maintained in DMEM:F12 (Media-
tech, Manassas, VA) supplemented with 10% fetal bovine
serum in the presence of 5% CO2 at 37°C. Cells were
routinely tested for Mycoplasma infection and were
authenticated by short tandem repeat analysis by UT
MD Anderson Cancer Center’s Characterized Cell Line
Core facility. Colony formation assays were performed
as described [2].
siRNA transfections were performed with ON-TARGET-
plus siATG7, siBECN1 SMARTpool or ON-TARGETplus
siCONTROL (siCONT) (Dharmacon, Lafayette, CO).
Dharmafect 4 was used to transfect 1.5 × 106 MCF-7 cells
with 600 pmoles siRNA as per the manufacturer’s proto-
col (Dharmacon). Expression knockdown was allowed to
proceed for ~2-days before reseeding for treatment ana-
lysis. GFP-LC3 expression construct was obtained from
Dr. Gordon Mills in the Department of Systems Biology,
UT MD Anderson Cancer Center. Using Nucleofector
Kit V, programs P-20 and T-20, respectively, (Amaxa
Biosystems, Koeln, Germany), 2 × 106 MCF-7 and BT-474
cells were transfected with 2 μg DNA. After transfection,
cells were cultured for 1-day prior to selection with
500 μg/ml G418 > 4 weeks to obtain pools of stably
transfected GFP-LC3 expressing cells.
Measurement of glycolysis, oxygen consumption, and
intracellular NTPs
OCR was measured using XF 96 Extracellular Analyzer
instrument (Seahorse Bioscience Inc., Chicopee, MA).
MCF7 and BT474 cells were plated at 30,000 cells per
well on XF96 cell culture microplate in 100 μl of culture
media. Cells were treated with 10 μM 8-Cl-Ado for 18 hrs.
Media was then replaced with fresh XF assay medium
(Seahorse Bioscience Inc.), supplemented with 17.5 mM
Glucose and 2 mM Sodium Pyruvate, (175 μl/well) and is
incubated in a CO2 free chamber of XF Prep station for
1 hr. XF Cell Mito Stress Test assay was performed as per
the manufacturer’s instructions using the following finalconcentrations; 1.25 μM oligomycin, 1 μM FCCP, 0.75 μM
antimycin and 1.25 μM rotenone (Seahorse Bioscience
Inc.). Each assay was repeated at least twice. For ECAR,
the culture media was replaced with glycolysis stress test
media (prepared in accordance with Seahorse Glycolysis
stress kit) supplemented with 2 mM of fresh L-Glutamine.
For the glycolysis assay, all ports were injected with 25 μl
of drugs for the following final concentrations; Port
A-10 mM glucose, Port B −1.25 oligomycin, Port C–
100 mM 2-deoxyglucose.
Perchloric acid was used to extract NTPs from MCF-7
and BT-474 cells treated with 10 μM 8-Cl-Ado and neu-
tralized extracts were analyzed by HPLC (Waters 600E
System Controller; Waters Corp., Milford, MA, USA) as
described [2].
Flow cytometry
Analysis of annexin V and PI labeling was performed as
described [2]. To detect and quantify the development
of 8-Cl-Ado-induced AVO, treated and untreated MCF-7
and BT-474 cells were stained directly in culture with
1 μg/ml acridine orange (Invitrogen) for 15 minutes at 37°C
essentially as described [47]. Thirty minutes prior to
staining, 0.1 μg/ml Baf was added to a duplicate culture
of 8-Cl-Ado treated cells as a control for negative AVO
staining. Cells treated with 50 nM rapamycin were used
as a positive control. Cells were removed from the plate
with Accumax (Fisher Scientific) and combined with
pellets of cells detached during treatment, then analyzed
using a Becton Dickinson FACSCalibur flow cytometer
and CellQuest software (San Jose, CA, USA).
Immunoblot analysis
Exponentially growing cells were treated with 10 μM
8-Cl-Ado for various amounts of time and protein lysates
were isolated and analyzed using an Odyssey Infrared
Imaging System (LI-COR Biosciences) as described [19].
Primary antibodies were rabbit polyclonal antibodies against
p-AMPKα (Thr172), AMPKa, p-acetyl-coA carboxylase
(ACC) (Ser79), p-raptor (Ser792), p-mTOR (Ser2481), p4E-
BP1 (Ser65) (Cell Signaling Technology), LC3B, beclin
1 (Novus Biologicals, Inc, Littleton, CO), p62 (Enzo Life
Sciences, Farmingdale, NY); rabbit monoclonal antibodies
against p-ULK1 (Ser555) clone D1H4, raptor clone 24C12,
mTOR clone 7C10 (Cell Signaling Technology), ATG7
(Novus Biologicals, Inc, Littleton, CO); mouse monoclonal
antibodies GAPDH clone 6C6 (Abcam, Inc, Cambridge,
MA); and goat polyclonal antibody 4E-BP1 (Santa Cruz
Biotechnology, Inc, Santa Cruz, CA).
Microscopic labeling of autophagic vesicles
MCF-7 cells were seeded overnight into 4 well chamber
slides at a density of 1.5 × 104 cells/chamber followed
by a 72-hours treatment with or without either 10 μM
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incubating cells in 50 mM MDC (Sigma-Aldrich) in PBS
at 37°C for 10 minutes and then washed three times with
PBS. Nuclei were counter stained with 5 μM SYTO 61
(Invitrogen) in Tris-buffered saline (25 mM Tris, 150 mM
NaCl, pH 7.5) at 37°C for 10 minutes and then washed
twice with PBS and immediately analyzed at UT MD
Anderson Cancer Center’s Flow Cytometry and Cellular
Imaging Core Facility by fluorescence microscopy using
an inverted microscope (Olympus 1X71, Melville, NY)
equipped with a filter system (excitation filter: 350/50 nm,
emission filter: 528/38 nm). Images were obtained with a
Hamamatsu Orca II ER camera (Hamamatsu, Japan) and
processed using the program Slidebook (3I, Denver, CO).
Xenograft studies
MCF-7 and BT474 xenografts were established in 4- 6-
week-old nu/nu female athymic nude mice (Department
of Experimental Radiation Oncology Animal Facility, The
University of Texas MD Anderson Cancer Center) supple-
mented with 0.72 mg 60-day release 17β-estrogen pellets
(Innovative Research of America, Sarasota, FL) by inocu-
lating 5 × 106 MCF-7 cells or 1 × 107 BT474 cells into two
sites of the mammary fat pads [48,49]. When maximum
tumor diameters reached ~3 mm, the animals were
randomly allocated (8–10 mice per group) for a 3 weeks
i.p. treatment with 8-Cl-Ado dissolved in PBS (0 or
100 mg/kg, 3 days/week). Body weight and tumor growth
were assessed 3 days/week and maximum tumor diame-
ters were recorded. Shortly after the end of the treatment
(1–3 days), the mice were sacrificed, tumors were col-
lected and tumor volumes were calculated in mm3 using
the formula length × width × height × π/6. All experiments
involving animals were performed in accordance with
the guidelines of the Institutional Animal Care and Use
Committee.
Statistical analysis
All graphing, statistical, and regression analysis was
performed using Prism software (GraphPad Software,
San Diego, CA). The elimination of 8-Cl-ATP was examined
by one phase and two phase decay nonlinear regression
analysis.
Additional file
Additional file 1: Figure S1. Effect of 8-Cl-Ado on the survival of breast
cancer cells. Figure S2: Accumulation of 8-Cl-ATP and effects on ATP
production. Figure S3: 8-Cl-Ado-induces autophagy.
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